仟源醫藥(300254.SZ):子公司收到“分泌抗可替寧單克隆抗體雜交瘤細胞珠和抗可替寧單克隆抗體及其應用”的發明專利證書
格隆匯5月17日丨仟源醫藥(300254.SZ)公佈,公司子公司杭州仟源恩氏基因技術有限公司於近日收到國家知識產權局頒發的“分泌抗可替寧單克隆抗體雜交瘤細胞珠和抗可替寧單克隆抗體及其應用”發明專利證書。
分泌抗可替寧單克隆抗體雜交瘤細胞株和抗可替寧單克隆抗體及其應用,提供了一種分泌高靈敏、高特異的抗可替寧單克隆抗體雜交瘤細胞株及其抗體在可替寧快速檢測領域的應用。可替寧是環境煙草煙霧中主要物質尼古丁在人體內的代謝產物,它是目前公認的評估受檢者煙草暴露程度、吸煙量以及吸煙對人體健康影響程度最有效的生物標誌物。本專利生產的抗可替寧單克隆抗體以其特有的高靈敏度和高特異性,目前已完成方法研發並應用於可替寧快速檢測產品的生產中。新專利的取得不會對公司生產經營產生重大影響,但有利於公司進一步完善知識產權保護體系,對提升公司的核心競爭力有着積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.